Aristotle University Of Thessaloniki (AUTH)
Η επίδραση των αναστολέων της αρωματάσης P450 στα ινομυώματα της μήτρας
Abstract
dc:descriptionObjective: To evaluate the effect of the aromatase P450 inhibitor, anastrazole, on symptomatic uterine leiomyomas. Methods: Prospective intervention study carried out in the 4th Department of Obstetrics and Gynaecology and the Department of Biochemistry of the Aristotle University of Thessaloniki. Forty-one premenopausal women eligible for hysterectomy with forty-five uterine leiomyomas were enrolled and treated with anastrazole 1 mg daily for three cycles of 28 days each. Twenty of the participants underwent transcervical ultrasound guided needle puncture leiomyoma tissue retrieval at baseline and at the end of the treatment protocol. Leiomyoma tissue retrieval was performed during surgery in women who elected surgical treatment at the end of the study. The effect of treatment was evaluated on leiomyoma and uterine volumes, endometrial thickness and histology, gonadotrophins, estradiol and hematocrit levels, menstrual pattern, severity of leiomyoma related symptoms, molecular expression of Transforming Growth Factor - β3 (TGF-β3), Vascular Endothelial Growth Factor (VEGF) and apoptosis protein Bcl-2 in leiomyoma tissue, using the RT-PCR method, and adverse effects of therapy. The effect of leiomyoma location, size and age of participants on tumour volume changes was evaluated. Results: Thirty-five women with thirty-nine leiomyomas finished the study. Anastrazole resulted in a mean 55.74% reduction of leiomyoma volumes (162.66 mL to 72 mL, p<.001), a 29.85% reduction in total uterine volumes (278.17 mL to 195.15 mL, p<.001), and an 11.28% increase of the hematocrit levels (33.43% to 37.20%, p<.001) at the end of the treatment. Leiomyoma location did not have a significant effect on volume decrease. Leiomyoma volume decreased significantly in women over 40 years of age (p=.002), whereas no significant difference was found in women younger than 40. The size of large (>50 mm) leiomyomas decreased significantly (p=.004). A less significant difference was observed in small (<=50 mm) leiomyomas (p=.031). No significant differences were detected in hormonal status. The mean expression of TGF-β3 tended to be lower at the end of treatment (p=.109). No significant difference in the expression of VEGF and Bcl-2 was observed. TGF-β3 tended to overexpress in the luteal phase of the cycle (p=.212), whereas the expression of VEGF and Bcl-2 did not exhibit any significant differences according to the phase of the cycle. No significant correlation between the initial leiomyoma volume and the expression of TGF-β3, VEGF and Bcl-2 was observed. No significant correlation between leiomyoma volume decrease and TGF-β3 expression decrease was observed. The expression of Bcl-2 correlated to the expression of TGF-β3 (r:0.17, p=.007) and VEGF (r:0.46, p=.002). Anastrazole improved leiomyoma related symptomatology and did not exhibit serious adverse effects. Conclusions: In premenopausal women, anastrazole reduces the size of uterine leiomyomas, improves symptomatology and is generally well tolerated. The TGF-β3 changes as well as the interactions between the growth factors TGF-β3 and VEGF and the apoptosis protein Bcl-2 may constitute part of the molecular mechanisms regulating leiomyoma growth.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2008
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Varelas, Fotios
- Βαρελάς, Φώτιος
Subjects
dc:subject × 19- Ινομυώματα
- Αναστραζόλη
- Προεμμηνοπαυσιακή
- Μηνορραγία
- Μετατρεπτικός αυξητικός παράγοντας β3
- Αγγειακός ενδοθηλιακός αυξητικός παράγοντας (VEGF)
- Leiomyomas
- Anastrazole
- Premenopausal
- Menorrhagia
- TGF-β3
- Transforming growth factor-β3
- VEGF (Vascular endothelium growth factor)
- Vascular endothelial growth factor (VEGF)
- Bcl-2
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/19128